ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

PSMA and Beyond 2025 PSMAfore trial, SPLASH trial, ECLIPSE trial, PSMA radioligand therapy, PSMAfore compared to SPLASH, SPLASH LuPSMA arm, PSMAfore LuPSMA arm, ProstACT GLOBAL.

The 34rd World Congress of Endourology (WCE) held in Conjunction with the South African Urological Association (SAUA) Meeting in 2016 was held in Cape Town, South Africa from November 8th-12th, 2016.

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate ...

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. August 7, 2025 ...

male incontinence advanced treatments, stem cell therapy male incontinence, ProACT periurethral balloons, male incontinence clinical decision making, Analysis of Treatment Options for Male Stress ...

Male accessory gland infection (MAGI) is a significant yet often under-recognized contributor to male infertility. This review article provides a comprehensive synopsis of MAGI, distinguishing it from ...